167 related articles for article (PubMed ID: 34057231)
1. Barriers and facilitators of germline genetic evaluation for prostate cancer.
Loeb S; Li R; Sanchez Nolasco T; Byrne N; Cheng HH; Becker D; Leader AE; Giri VN
Prostate; 2021 Aug; 81(11):754-764. PubMed ID: 34057231
[TBL] [Abstract][Full Text] [Related]
2. Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation
Loeb S; Byrne N; Walter D; Makarov DV; Wise DR; Becker D; Giri VN
Cancer Treat Res Commun; 2020; 25():100212. PubMed ID: 33091732
[TBL] [Abstract][Full Text] [Related]
3. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Paller CJ; Antonarakis ES; Beer TM; Borno HT; Carlo MI; George DJ; Graff JN; Gupta S; Heath EI; Higano CS; McKay RR; Morgans AK; Patnaik A; Petrylak DP; Rettig MB; Ryan CJ; Taplin ME; Whang YE; Vinson J; Cheng HH; Giri VN;
Clin Genitourin Cancer; 2019 Aug; 17(4):275-282.e1. PubMed ID: 31171481
[TBL] [Abstract][Full Text] [Related]
4. Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice.
Giri VN; Walker A; Gross L; Trabulsi EJ; Lallas CD; Kelly WK; Gomella LG; Fischer C; Loeb S
Clin Genitourin Cancer; 2022 Apr; 20(2):e104-e113. PubMed ID: 35012874
[TBL] [Abstract][Full Text] [Related]
5. Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care.
Mark JR; McDougall C; Giri VN
Urol Clin North Am; 2021 Aug; 48(3):311-322. PubMed ID: 34210487
[TBL] [Abstract][Full Text] [Related]
6. Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists.
Kim SP; Meropol NJ; Gross CP; Tilburt JC; Konety B; Yu JB; Abouassaly R; Weight CJ; Williams SB; Shah ND
Urol Oncol; 2018 Nov; 36(11):501.e15-501.e21. PubMed ID: 30190177
[TBL] [Abstract][Full Text] [Related]
7. A qualitative study to understand guideline-discordant use of imaging to stage incident prostate cancer.
Makarov DV; Sedlander E; Braithwaite RS; Sherman SE; Zeliadt S; Gross CP; Curnyn C; Shedlin M
Implement Sci; 2016 Sep; 11(1):118. PubMed ID: 27590603
[TBL] [Abstract][Full Text] [Related]
8. An Evolving Relationship Between Medical Oncologists and Genetic Counselors in Prostate Cancer.
Gong J
Oncology (Williston Park); 2021 Oct; 35(10):650. PubMed ID: 34669359
[No Abstract] [Full Text] [Related]
9. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.
Loeb S; Giri VN
Eur Urol Oncol; 2021 Feb; 4(1):1-9. PubMed ID: 33390340
[TBL] [Abstract][Full Text] [Related]
10. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling.
Giri VN; Obeid E; Hegarty SE; Gross L; Bealin L; Hyatt C; Fang CY; Leader A
Prostate; 2018 Sep; 78(12):879-888. PubMed ID: 29655297
[TBL] [Abstract][Full Text] [Related]
11. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
Giri VN; Knudsen KE; Kelly WK; Cheng HH; Cooney KA; Cookson MS; Dahut W; Weissman S; Soule HR; Petrylak DP; Dicker AP; AlDubayan SH; Toland AE; Pritchard CC; Pettaway CA; Daly MB; Mohler JL; Parsons JK; Carroll PR; Pilarski R; Blanco A; Woodson A; Rahm A; Taplin ME; Polascik TJ; Helfand BT; Hyatt C; Morgans AK; Feng F; Mullane M; Powers J; Concepcion R; Lin DW; Wender R; Mark JR; Costello A; Burnett AL; Sartor O; Isaacs WB; Xu J; Weitzel J; Andriole GL; Beltran H; Briganti A; Byrne L; Calvaresi A; Chandrasekar T; Chen DYT; Den RB; Dobi A; Crawford ED; Eastham J; Eggener S; Freedman ML; Garnick M; Gomella PT; Handley N; Hurwitz MD; Izes J; Karnes RJ; Lallas C; Languino L; Loeb S; Lopez AM; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann M; Mille P; Miner MM; Morgan T; Moreno J; Mucci L; Myers RE; Nielsen SM; O'Neil B; Pinover W; Pinto P; Poage W; Raj GV; Rebbeck TR; Ryan C; Sandler H; Schiewer M; Scott EMD; Szymaniak B; Tester W; Trabulsi EJ; Vapiwala N; Yu EY; Zeigler-Johnson C; Gomella LG
J Clin Oncol; 2020 Aug; 38(24):2798-2811. PubMed ID: 32516092
[TBL] [Abstract][Full Text] [Related]
12. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Care Related to Post-Operative Radiotherapy for Patients with Prostate Cancer among Canadian Radiation Oncologists and Urologists.
Bristow B; Aldehaim M; Bonin K; Lam CCK; Wan SJ; Cao X; Szumacher E
J Cancer Educ; 2018 Dec; 33(6):1195-1200. PubMed ID: 28573519
[TBL] [Abstract][Full Text] [Related]
14. Radiation oncologists' attitudes and beliefs about intensity-modulated radiation therapy and stereotactic body radiation therapy for prostate cancer.
Jacobs BL; Hamm M; de Abril Cameron F; Luiggi-Hernandez JG; Heron DE; Kahn JM; Barnato AE
BMC Health Serv Res; 2020 Aug; 20(1):796. PubMed ID: 32843034
[TBL] [Abstract][Full Text] [Related]
15. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.
Szymaniak BM; Facchini LA; Giri VN; Antonarakis ES; Beer TM; Carlo MI; Danila DC; Dhawan M; George D; Graff JN; Gupta S; Heath E; Higano CS; Liu G; Molina AM; Paller CJ; Patnaik A; Petrylak DP; Reichert Z; Rettig MB; Ryan CJ; Taplin ME; Vinson J; Whang YE; Morgans AK; Cheng HH; McKay RR
JCO Oncol Pract; 2020 Dec; 16(12):811-819. PubMed ID: 32986533
[TBL] [Abstract][Full Text] [Related]
16. A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer.
Kim SP; Tilburt JC; Shah ND; Yu JB; Konety B; Nguyen PL; Abouassaly R; Williams SB; Gross CP
Clin Genitourin Cancer; 2019 Jun; 17(3):e472-e481. PubMed ID: 30827923
[TBL] [Abstract][Full Text] [Related]
17. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
[TBL] [Abstract][Full Text] [Related]
18. Bladder-sparing Radiotherapy for Muscle-invasive Bladder Cancer: A Qualitative Study to Identify Barriers and Enablers.
Walker M; Doiron RC; French SD; Feldman-Stewart D; Siemens DR; Mackillop WJ; Booth CM
Clin Oncol (R Coll Radiol); 2017 Dec; 29(12):818-826. PubMed ID: 28951003
[TBL] [Abstract][Full Text] [Related]
19. Factors that influence clinicians' decisions to decrease active surveillance monitoring frequency or transition to watchful waiting for localised prostate cancer: a qualitative study.
Lowenstein LM; Choi NJ; Hoffman KE; Volk RJ; Loeb S
BMJ Open; 2021 Nov; 11(11):e048347. PubMed ID: 34772748
[TBL] [Abstract][Full Text] [Related]
20. ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.
Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes K; Wheeler SB
Int J Technol Assess Health Care; 2016 Jan; 32(5):355-361. PubMed ID: 27958190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
